Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT07281781

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

Led by University of California, Irvine · Updated on 2026-05-04

10

Participants Needed

1

Research Sites

89 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.

CONDITIONS

Official Title

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Diagnosed with myelofibrosis according to the 2016 WHO criteria
  • Hemoglobin level 10 gm/dL or less at screening
  • Serum ferritin 100 or higher
  • May continue current MPN treatments including aspirin, hydroxyurea, interferon-alpha, ruxolitinib, fedratinib, or anagrelide
  • Peripheral blast count less than 10% during screening
  • Free of other active or metastatic cancers except localized skin cancer
  • Able to undergo blood draws and symptom assessments
  • Agree to use effective contraception during the study and for 60 days after last dose
Not Eligible

You will not qualify if you...

  • Eastern Cooperative Oncology Group (ECOG) score of 3 or higher
  • Currently pregnant or planning pregnancy during the study
  • Taking Momelotinib or Pacritinib
  • Taking any medications contraindicated with Nelfinavir
  • Currently breastfeeding
  • Known uncontrolled active viral or bacterial infection
  • Known HIV positive
  • Significant major organ or blood function impairment including:
  • Serum creatinine clearance less than 30 ml/min (eGFR)
  • Bilirubin over 1.5 mg/dl except Gilbert's disease, or ALT/AST over twice the normal limit, or liver cirrhosis seen on imaging
  • Platelet count below 50 x 10^9/L without transfusions
  • Absolute neutrophil count below 0.75 x 10^9/L without growth factors
  • Known allergy to Nelfinavir

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chao Family Comprehensive Cancer Center, University of California, Irvine

Orange, California, United States, 92868

Actively Recruiting

Loading map...

Research Team

C

Chao Family Comprehensive Cancer Center University of California, Irvine

CONTACT

U

University of California Irvine Medical

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow | DecenTrialz